Spago Nanomedical AB (publ) at the moment introduced that an summary, concluding the preliminary outcomes from the First-In-Human Section I medical trial SPAGOPIX-01, has been accepted for poster presentation on the 2022 San Antonio Breast Most cancers Symposium® (SABCS) on December 6-10, 2022.
The summary, titled Security, tolerability, and efficacy of the novel intravenous manganese-based distinction agent SN132D in sufferers with breast most cancers: preliminary outcomes of a Section I, First-In-Human medical trial SPAGOPIX-01, will likely be introduced on the 2022 San Antonio Breast Most cancers Symposium by the coordinating investigator Dr. Fredrik Wärnberg, professor and breast surgical procedure specialist at Sahlgrenska College Hospital.
The preliminary outcomes from the open-label, non-randomized and non-placebo-controlled Section I examine SPAGOPIX-01, evaluating the drug candidate SN132D, show an appropriate security profile and PoC for SN132D in breast most cancers sufferers. Physiological focusing on with useful nanoparticles seems to be appropriate for tumor MRI imaging and the information generated up to now are in settlement with preclinical knowledge in rodent tumor fashions. The information relies on 12 feminine breast most cancers sufferers enrolled within the examine between September 2019 and December 2021.
“This is a vital recognition of our distinction agent SN132D and additional strengthen our confidence in its potential to enhance the precision of most cancers diagnostics. These first knowledge additionally assist the continuation of the SPAGOPIX-01 medical trial and we expanded it to additionally discover SN132D in a cohort of pancreatic most cancers sufferers with liver involvement,” mentioned Mats Hansen, CEO at Spago Nanomedical.